louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04430764: The Effect of Smoking and Non-surgical Periodontal Treatment on Gingival Crevicular Fluid Cyclophilin A and EMMPRIN Levels
Official title: The Effect of Smoking and Non-surgical Periodontal Treatment on Gingival Crevicular Fluid Cyclophilin A and EMMPRIN Levels
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking
Periodontitis
Non-surgical Periodontal Treatment
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2020-06-12
Enrollment: 58
Sex: ALL
Minimum age (years): 29
Maximum age (years): 61
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to investigate the effect of smoking and non-surgical periodontal treatment on gingival crevicular fluid CyPA and EMMPRIN levels in patients with periodontitis. Twenty-eight patients with periodontitis (14 non-smoker and 14 smoker) and 30 control subjects (15 non-smoker and 15 smoker) were included into the study. Non-surgical periodontal treatment was applied to all periodontitis patients. Periodontal parameters and GCF CyPA and EMMPRIN levels were evaluated during 3 months following non-surgical periodontal treatment. GCF CyPA and EMMPRIN levels were analyzed by ELISA.


Eligibility criteria: Inclusion Criteria:

* generalized periodontitis with stage III-IV \& Grade B
* no systemic and periodontal diseases
* smokers (minimum 10 cigarettes per day for at least ten years)
* non-smokers (never smoked)

Exclusion Criteria:

* Systemic diseases
* Infectious diseases
* Pregnancy or lactating
* Having periodontal treatment during the last 6 months
* Having antibiotic treatment within the past 3 months
* Former smokers

Primary outcomes:
measure: Change in gingival crevicular fluid CypA total amounts
timeFrame: Baseline, 1 week, 1., 3. months
measure: Change in gingival crevicular fluid EMMPRIN total amounts
timeFrame: Baseline, 1 week, 1., 3. months
Secondary outcomes:
measure: Change in probing depth
timeFrame: Baseline, 1., 3. months
measure: Change in bleeding on probing
timeFrame: Baseline, 1., 3. months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05793164: Characterization and Risk Factors of Folliculitis After Hair Transplantation
Official title: Characterization and Risk Factors of Folliculitis After Hair Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Folliculitis
Keywords: folliculitis
hair transplantation
Follicular Unit Extraction
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2023-03-31
Enrollment: 1317
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Data of 1317 patients who had undergone HT and completed a 9-month follow-up from January 2018 to June 2021 were collected.

Brief summary: We retrospectively reviewed 1317 patients who had undergone HT and completed 9-month follow-up between January 2018 and June 2021 at 4 medical centers. The incidence of postoperative folliculitis and the patient demographics were assessed. Logistic regression analysis was used to identify the risk factors, and the characteristics of different types of folliculitis were compared.

Detailed description: Postoperative folliculitis is a common complication after hair transplantation (HT) and requires effective preventive interventions. This study aimed to characterize postoperative folliculitis and determine the risk factors in patients underwent HT. The study was conducted at 4 clinical sites: Nanfang Hospital of Southern Medical University, the First Affiliated Hospital, Zhejiang University School of Medicine, the Affiliated Hospital of Guilin Medical University, and Peking University Third Hospital. Data of 1317 patients who had undergone HT and completed a 9-month follow-up from January 2018 to June 2021 were collected. The incidence of postoperative folliculitis and the patient demographics were assessed. Logistic regression analysis was used to identify the risk factors, and the characteristics of different types of folliculitis were compared.

Eligibility criteria: Inclusion Criteria:

- 1. Healthy adults between the ages of 18 \~ 60

2. patients suitable for autologous hair transplantation according to "the standard of hair transplantation"

Exclusion Criteria:

1. Coagulation disorders, pregnancy and lactation, immunosuppression
2. With severe mental and psychological illness, impairment of body image
3. All kinds of immune-related alopecia in the progressive active stage
4. Patients judged by the investigator to be unsuitable for this study

Primary outcomes:
measure: folliculitis
timeFrame: 9 months after hair transplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Nanfang Hospital of Southern Medical University
state: Guangdong
Study officials:
affiliation: Nanfang Hospital, Southern Medical University
name: Zhiqi Hu, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02495064: Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients
Official title: Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Early Radiation Dermatitis
Lead sponsor: Mianyang Central Hospital
Sponsor class: OTHER
First posted: 2015-07-13
Enrollment: 160
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Radiation dermatitis is an acute effect of radiation therapy,Especially in the neck skin of head and neck squamous cell carcinomas' patients.The investigators wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study.

Detailed description: A randomized,self-comparative controlled trial was undertaken comparing MF cream with no cream administered from the first day of treatment for 5-6 weeks to prevent radiation dermatitis of neck during radiation therapy to the head and neck squamous cell carcinomas' Patients.

One side of patients' neck will begin to use MF cream from the first day of radiation therapy, while the other side accept no preventive measures.

Eligibility criteria: Inclusion Criteria:

* pathological diagnosis for head and neck squamous cell carcinomas and
* going to have radiotherapy.

Exclusion Criteria:

* pregnant,
* lactating women,
* infants,
* elderly people with atrophy skin,
* allergic constitution patients,
* the corresponding parts of 5 radiotherapy skin ulceration or infection and
* allergic patients to Mometasone Furoate Cream.

Primary outcomes:
measure: the mean Radiation Therapy Oncology Group (RTOG) skin dermatitis score
timeFrame: seven weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Mianyang
country: China
facility: oncology department of Mian yang central Hosptial
state: Sichuan
Study officials:
affiliation: Health Bureau of Mian Yang
name: Wang dong
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02319564: Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children
Official title: Randomized Trial Assessing the Effectiveness of Beclomethasone and Combination Beclomethasone and Salbutamol as Compared With Placebo in Preschool Aged Children With Wheeze
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Wheeze
Keywords: Wheeze
Asthma
Randomized Trial
Pre-school aged children
Lead sponsor: University of Calgary
Sponsor class: OTHER
Collaborators: name: Children's Hospital of Eastern Ontario
First posted: 2014-12-18
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Maximum age (years): 60
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators goal is to conduct a pilot randomized controlled trial (RCT) whose purpose is to determine the feasibility of a randomized trial designed to determine if either inhaled beclomethasone or a combination of inhaled beclomethasone/salbutamol (Clenil Compositum) are superior to placebo in treating pre-school aged children with an acute wheezing episode.


Eligibility criteria: Inclusion Criteria:

1. children 12-60 months of age
2. wheeze on auscultation
3. mild respiratory distress as measured by a score of \< 3 on the Pediatric Respiratory Assessment Measure (PRAM)
4. discharged home after evaluation by their ED physician.

Exclusion Criteria:

1. treatment with oral or parenteral corticosteroids in the last 14 days
2. treatment with more than 2 doses of inhaled corticosteroids in the previous seven days
3. presence of a severe co-morbidity such as bronchopulmonary dysplasia, cystic fibrosis, congenital heart disease, adrenal disorder or immune deficiency
4. previously enrolled into this study or concurrently enrolled in another intervention trial
5. lack of telephone access or presence of a significant language barrier

Primary outcomes:
measure: Reduce unplanned-symptomatic visits to clinicians
timeFrame: After enrolment is complete
Secondary outcomes:
measure: Reduce the number of days with respiratory symptoms
timeFrame: Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days
measure: Reduce the need for rescue salbutamol use
timeFrame: Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days
measure: Reduce hospitalization rates of target population
timeFrame: Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days
measure: Reduce overall societal health care costs of target population
timeFrame: Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Alberta Children's Hospital
state: Alberta
Study officials:
References:
Clinical trial NCT05161364: Kinetic Analysis Due to Foot Dysfunction
Official title: Analysis of Gait Kinetics in Patients With Foot Dysfunction Either Physiological or Anatomical
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Amputation
Neuropathy;Peripheral
Lead sponsor: Delta University for Science and Technology
Sponsor class: OTHER
First posted: 2021-12-17
Enrollment: 70
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Convenient 70 patients with 35 patients in each group of both genders ranging in age from 40 to 65 years will participate in this study after examination to exclude any defined pathological conditions. Participants will be recruited from foot amputation centers and outpatient clinics in Mansoura and Damietta, Egypt. All the participants were capable of walking independently to perform their activities of daily life with or without a walking aid. However, no walking aids were used during the testing procedures.

Brief summary: The aim of the current study is to examine the biomechanical changes of gait kinetics in patients with either partial foot amputation or peripheral neuropathy


Eligibility criteria: Inclusion Criteria:

* Partial foot amputees who didn"t receive physiotherapy and don"t use prosthesis. patients with PN grade (1-2) Age 40-65y Both sexes. Walking independently however, no walking aids were used during the testing procedures

Exclusion Criteria:

* Foot amputation levels more proximal than tarso metatarsal joint. Less than 4 months after partial foot amputation. Foot amputees who use prosthesis or suffer from phantom pain. Active foot problems; ulcer, infection, or gangrene. Patients with PN who received physiotherapy or injections like Puerarin Major surgeries in lower limb that could affect either gait or balance like ACL, hip/knee arthroplasty Spine problems that could affect either gait or balance History of ankle sprain. Pathologies such as skin diseases, inflammatory diseases, congenital diseases, or neurological diseases rather than PN.

Fractures or dislocations. Symptomatic degenerative changes that require medications. BMI over 35. Inability of walking independently

Primary outcomes:
measure: GRF
timeFrame: 5 minutes
measure: Planter Pressure
timeFrame: 3 minutes
measure: Planter Pressure distribution
timeFrame: 4 minutes
measure: Foot surface area
timeFrame: 6 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Gamasa
country: Egypt
facility: Delta university
state: Eldakahlyia
Study officials:
References:
Clinical trial NCT00662064: Pharmacology and Physiology of the Lower Urinary Tract
Official title: Pharmacology and Physiology of the Lower Urinary Tract
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Urologic Diseases
Keywords: Lower urinary tract
Physiology
Pathology
Immunohistochemistry
Urinary bladder
Lead sponsor: University College London Hospitals
Sponsor class: OTHER
First posted: 2008-04-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with lower urinary tract dysfunction and controls with normal lower urinary tract function

Brief summary: The function of the lower urinary tract is simple - urine storage and voiding. However, despite this simplicity of function, the control of the lower urinary tract is a rather complex, multilevel process (urothelium, detrusor, peripheral nerves, spinal cord and higher cerebral centres) and the mechanisms involved remain poorly elucidated.

This study is designed to gain a more in depth understanding of the lower urinary tract function. Using bladder biopsies, tissue staining for characteristic markers present on nerves and other cells will be performed. We hypothesize that certain markers are altered in disease and turn back towards the control level of healthy people or patients with successful medical treatment.


Eligibility criteria: Inclusion Criteria:

* Patients with lower urinary tract dysfunction
* Controls with normal lower urinary tract function

Exclusion Criteria:

* Age \< 18 years old
* Pregnancy

Primary outcomes:
measure: Immunohistochemistry + PCR of bladder tissue
timeFrame: not specified (storage of biopsies)
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery
Study officials:
affiliation: Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, UK
name: Clare J Fowler, FRCP
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, UK
name: Suzy Elneil, PhD, MRCOG
role: PRINCIPAL_INVESTIGATOR
References:
citation: Roosen A, Datta SN, Chowdhury RA, Patel PM, Kalsi V, Elneil S, Dasgupta P, Kessler TM, Khan S, Panicker J, Fry CH, Brandner S, Fowler CJ, Apostolidis A. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol. 2009 Jun;55(6):1440-8. doi: 10.1016/j.eururo.2008.11.009. Epub 2008 Nov 18.
Clinical trial NCT01019564: Complete Easy Rub Comparative Efficacy Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Myopia
Hyperopia
Astigmatism
Lead sponsor: Abbott Medical Optics
Sponsor class: INDUSTRY
First posted: 2009-11-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this trial is to assess Complete Easy Rub compared to a competitor multi-purpose solution in terms of lens cleanliness, subjective response and ocular response, when lenses are worn bilaterally on a daily wear basis for two months.

The hypotheses for this trial are:

* Lens cleanliness measures between solutions will be no different.
* Subjective ratings between solutions will be no different.
* Ocular response between solutions will be no different.


Eligibility criteria: Inclusion Criteria:

* Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;
* Be at least 18 years old, male or female;
* Willing to comply with the wearing and clinical trial visit schedule as directed by the investigator;
* Have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses;
* Is correctable to at least 6/12 (20/40) or better in each eye with contact lenses;
* Able to successfully wear one of the lens types to be used in this study on a daily wear (DW) basis in conjunction with any multi-purpose contact lens care solution (not including hydrogen peroxide-based systems) for at least one month prior to allocation of test or control solution;

Exclusion Criteria:

* Any pre-existing ocular irritation, injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses;
* Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants;
* Use of, or a need for, concurrent category S3 and above ocular medication at enrolment and/or during the study;
* Use of, or a need for, any systemic medication or topical medications which may alter normal ocular findings/are known to affect a participant's ocular health/physiology or contact lens performance either in an adverse manner or beneficial manner at enrolment and/or during the study

Primary outcomes:
measure: Evaluation of lens cleanliness of test and control solutions when used with soft lenses at the end of the manufacturer-recommended replacement interval.
timeFrame: Day 30
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03730064: Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression
Official title: Neuroinflammation as a Novel Target to Treat Bipolar Depression: A Pilot PET Study With [11C]PBR-28 and N-Acetyl Cysteine (NAC) Antidepressant Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Bipolar Disorder
Depression
Keywords: Inflammation
NAC
N-acetyl cysteine
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
First posted: 2018-11-05
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process. If you participate, you will have two different brain scans (MRI and PET scan). You will also have an experimental treatment for your depression named N-acetyl cysteine (NAC). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder. Please contact us if you are interested in participating. Up to $600 in compensation if you are eligible and choose to participate. Up to 6 months of treatment for depression at no cost to you.


Eligibility criteria: Inclusion Criteria:

* Bipolar 2 disorder and meets criteria for a major depressive episode
* Age 18-60
* Females of child-bearing potential must be willing to use an acceptable method of birth control throughout the study
* Not currently taking psychotropic medications besides those allowed in the clinical trial

Exclusion Criteria:

* Failed trial or intolerable side effects of NAC
* Diagnosis of other major psychiatric disorders such as lifetime schizophrenia, schizoaffective disorder, psychotic features of bipolar disorder, current drug or alcohol abuse or recent drug or alcohol dependence
* Significant active physical illness, including blood dyscrasias, lymphomas, hypersplenism, endocrinopathies, renal failure, chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease. Any disorders with inflammation, malignancy, autoimmune or infectious etiology. Systolic blood pressure \>140 or diastolic blood pressure \> 100 Hemoglobin \<11 in females or \<13 in males
* Metal implants, pacemaker, metal prostheses, metal orthodontic appliances or shrapnel in the body
* Current, past or anticipated exposure to radiation

Primary outcomes:
measure: Montgomery Asberg Depression Rating Scale
timeFrame: Six weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
References:
Clinical trial NCT01718964: Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)
Official title: Acute Effects of Cortisol on Heroin Craving in Opioid Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid Dependence
Lead sponsor: University of Basel
Sponsor class: OTHER
First posted: 2012-11-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To investigate the effects of cortisol on heroin craving and stress reaction in heroin addicted subjects Randomized, double-blind, placebo-controlled, cross-over, single administration of study medication Study hypothesis:Cortisol has an inhibiting effect on heroin craving and stress reactivity in opioid dependent subjects.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18
* Opioid dependency
* Participant in the Janus heroin programme of the UPK Basel
* Able to control parallel consumption of other drugs
* Stable i.v. substitution for at least 3 months

Exclusion Criteria:

* co-morbid psychiatric disturbances
* Current medical conditions excluding participation
* Recent history of systemic or topic glucocorticoid therapy
* known hypersensitivity to the IMP under investigation (cor-tisol)
* pregnancy, breast-feeding
* inability to read and understand the participant's information

Primary outcomes:
measure: Heroin craving
timeFrame: baseline, change from baseline during and after presentation of drug stimuli
Secondary outcomes:
measure: Anxiety
timeFrame: baseline, change from baseline during and after presentation of drug stimuli
Other outcomes:
measure: Symptoms of withdrawal
timeFrame: baseline, change from baseline during and after presentation of drug stimuli
measure: saliva cortisol level
timeFrame: baseline, change from baseline during and after presentation of drug stimuli
Locations:
city: Basel
country: Switzerland
facility: Psychiatric Hospital
Study officials:
References:
citation: Walter M, Bentz D, Schicktanz N, Milnik A, Aerni A, Gerhards C, Schwegler K, Vogel M, Blum J, Schmid O, Roozendaal B, Lang UE, Borgwardt S, de Quervain D. Effects of cortisol administration on craving in heroin addicts. Transl Psychiatry. 2015 Jul 28;5(7):e610. doi: 10.1038/tp.2015.101.